Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gb Sciences Inc (OP: GBLX ) 0.0002 UNCHANGED Streaming Delayed Price Updated: 10:16 AM EST, Nov 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 22,276 Open 0.0002 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0002 Today's Range 0.0002 - 0.0002 52wk Range 0.0001 - 0.0135 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News GB Sciences Signs Letter of Intent for a License to Develop and Market Their Cannabinoid-Based Parkinson’s Formulation With Endopure Life Sciences July 02, 2024 Via ACCESSWIRE Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland(R) December 14, 2023 Via ACCESSWIRE Performance YTD -96.88% -96.88% 1 Month -96.36% -96.36% 3 Month -97.22% -97.22% 6 Month -96.97% -96.97% 1 Year -96.88% -96.88% More News Read More Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge July 11, 2023 Via ACCESSWIRE GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China March 20, 2023 Via ACCESSWIRE Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform March 07, 2023 Via ACCESSWIRE Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform December 22, 2022 Via Newswire.com Topics Death Exposures COVID-19 Death Marijuana And Chronic Pain: Gb Sciences' Nanoparticle Technology Boosts Efficacy Of Cannabis Terpenes March 29, 2022 Via Benzinga Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform December 22, 2022 From Gb Sciences Via GlobeNewswire Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations December 12, 2022 Via Newswire.com Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations December 12, 2022 From Gb Sciences Via GlobeNewswire Cannabis Terpenes Reduce Inflammation, Says Gb Sciences Study November 01, 2022 Via Benzinga Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients November 01, 2022 Via Newswire.com Topics Cannabis Exposures Cannabis Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study October 24, 2022 Via Newswire.com TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference October 13, 2022 Via Newswire.com Topics Cannabis Exposures Cannabis New Study Shows Promising Results In Treatment Of Parkinson's Disease With Cannabinoids October 10, 2022 Via Benzinga Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease October 10, 2022 Via Newswire.com Topics Cannabis Exposures Cannabis TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article September 06, 2022 Via Newswire.com Topics Cannabis Exposures Cannabis TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit May 23, 2022 Via Newswire.com Topics Intellectual Property Exposures Intellectual Property Product Safety TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit May 12, 2022 Via Newswire.com Topics Intellectual Property Exposures Intellectual Property TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference May 05, 2022 Via Newswire.com FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies May 02, 2022 Via Newswire.com Exposures COVID-19 Gb Sciences To Begin Dosage Study For Cannabinoid-Containing Drug For Treatment Of Parkinson's Disease April 12, 2022 Via Benzinga Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge April 12, 2022 Via Newswire.com Topics Intellectual Property Exposures Intellectual Property Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article March 29, 2022 Via Newswire.com UPDATE: Gb Sciences Issues Shareholder Letter March 16, 2022 Via Newswire.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
